Liminal BioSciences Inc.

Liminal BioSciences Inc.

LMNL

LMNLLiminal BioSciences Inc. US flag

NASDAQ Global Market

8.50

USD

+0.01

- -

27.62MMarket Cap

Liminal BioSciences Inc.

LMNL

(NASDAQ Global Market)

Recent

price

8.50

P/E

ratio

- -

div

yld

- -

ROIC.AI

No data availableFinancial data will appear here once available

Capital Structure

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Similar Companies: Enliven Therapeutics, Inc. (ELVN)
Ionis Pharmaceuticals, Inc. (IONS)
Organicell Regenerative Medicine, Inc. (BPSR)
Kintara Therapeutics, Inc. (KTRA)
Prelude Therapeutics Incorporated (PRLD)
Biotest AG (BIO3.DE)
Business: Liminal BioSciences Inc. is a development-stage biopharmaceutical company focused on discovering and developing novel and distinctive small molecule therapeutics that modulate G protein-coupled receptor (GPCR) pathways. The company designs proprietary small molecule therapeutic candidates aimed at developing best-in-class treatments for metabolic, inflammatory, and fibrotic diseases with significant unmet medical needs. Its core product candidates include LMNL6511, a selective antagonist for the GPR84 receptor, expected to enter Phase 1 clinical trials; LMNL6326, an antagonist for the OXER1 receptor targeting eosinophil-driven diseases; and GPR40 agonists, all in preclinical development. Liminal BioSciences operates primarily in Canada and the United Kingdom, with headquarters in Laval, Quebec, and was founded in 1994. Recently, Liminal BioSciences completed a going-private transaction through an arrangement agreement with Structured Alpha LP, a fund managed by Thomvest Asset Management Ltd., providing liquidity and strategic partnership benefits to the company. This transaction, completed in late 2023, supports the company’s continued focus on advancing its pipeline and exploring additional development opportunities. The company also announced clinical development milestones, such as the expected commencement of Phase 1 trials for LMNL6511 in the second half of 2023, marking a significant step in its product development. Additionally, Liminal BioSciences continues to leverage its drug discovery platform and medicinal chemistry expertise to advance novel therapies targeting complex diseases with unmet patient needs. Liminal BioSciences’ business segments concentrate on biopharmaceutical research and development, emphasizing small molecule medicines for rare and complex diseases. It serves global markets, focusing on patients with metabolic, inflammatory, and fibrotic disorders. Its wholly owned subsidiary, Caledon Bioscience Inc., supports its drug discovery and development efforts. The company’s approach integrates deep biological insights into GPCR pathways with a proprietary data-driven platform to create innovative therapeutic solutions. In summary, Liminal BioSciences engages in proprietary small molecule drug discovery and clinical development primarily for metabolic, inflammatory, and fibrotic diseases; it recently transitioned to private ownership under Structured Alpha LP and is advancing several clinical and preclinical candidates in North American and European markets. The company operates from Laval, Canada, with research hubs in the United Kingdom, maintaining a robust pipeline targeting diseases with high unmet medical needs using its focused expertise in GPCR biology and medicinal chemistry.

Company News